Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Adherium.
RELATED STOCKHEAD STORIES
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Tech, Retail, and Banking stocks feel the heat as ASX tumbles over 1pc
News
ASX Small Caps Lunch Wrap: Whose bark could be worse than their flight this week?
News
Top 10 at 10: This is what happens when AstraZeneca selects your tech for a clinical trial
Health & Biotech
Adherium’s focus on US market could pay off big time for its novel asthma device
News
Closing Bell: Geopolitical tensions, China’s economy roil the ASX as Aussie dollar trades below US65c
News
Top 10 at 10: Piedmont gets green light to build ‘one of the lowest cost, most sustainable lithium hydroxide operations in the world’
Health & Biotech
Check Up: Earnings season is almost here. Here’s how ASX biotech investors should read the 4C Report
Health & Biotech
Check Up: The reason people quit weight-loss drugs
News
Top 10 at 11: Major gains for sustainable ag after Roots flies a shipment out of Israel
News
Top 10 at 10: Health minnow 1st Group climbs on new contract in WA
Health & Biotech
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
News
Market Highlights: Powell speaks, ECB joins 75bp club, and 5 ASX small caps to watch on Friday
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Health & Biotech
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
Health & Biotech
